NAT10/ac4C/FOXP1 Promotes Malignant Progression and Facilitates Immunosuppression by Reprogramming Glycolytic Metabolism in Cervical Cancer

Immunotherapy has recently emerged as the predominant therapeutic approach for cervical cancer (CCa), driven by the groundbreaking clinical achievements of immune checkpoint inhibitors (ICIs), such as anti‐PD‐1/PD‐L1 antibodies. N4‐acetylcytidine (ac4C) modification, catalyzed by NAT10, is an import...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xiaona, Hao, Yi, Liu, Yong, Zhong, Sheng, You, Yuehua, Ao, Keyi, Chong, Tuotuo, Luo, Xiaomin, Yin, Minuo, Ye, Ming, He, Hui, Lu, Anwei, Chen, Jianjun, Li, Xin, Zhang, Jian, Guo, Xia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646273/
https://www.ncbi.nlm.nih.gov/pubmed/37818745
http://dx.doi.org/10.1002/advs.202302705

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646273/
https://www.ncbi.nlm.nih.gov/pubmed/37818745
http://dx.doi.org/10.1002/advs.202302705

Ejemplares similares